Oct 28HHS draft policy lets licensed pharmacies compound six peptides, including BPC-157. What changed and what did not.
Skip to content
PeptideAgent

NAD+ injections and IV therapy: do they work, are they legal, and what do they cost?

A coenzyme, not a peptide, whose precursors raise blood NAD+ in human RCTs; clinical benefits and IV NAD+ itself remain largely unproven.

By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed.  Last verified

Quick answers

Quick answers about NAD+
Does it work in people?Evidence: Human RCT evidence

At least one randomized human trial in PubMed. See the evidence

Is it legal?Regulatory: In FDA review (Category 1)

Not FDA approved. Pharmacies compound it under FDA's interim policy, where state boards permit, while FDA evaluates its nomination. [6] [12] See legal status

What does it cost?IV NAD+ at a published clinic menu costs about 450 to 900 USD per session for 500 to 1,000 mg (member prices from 400 USD); compounded subcutaneous NAD+ through telehealth is about 79 to 199 USD per month. Insurance does not cover it. See cost by channel
Side effects?Oral NR and NMN: generally well tolerated in trials; mild nausea, flushing, and fatigue reported. IV NAD+: infusion related chest pressure, nausea, cramping, flushing, and anxiety when given quickly (reported clinically; drives slow infusion rates). Injection site reactions with subcutaneous NAD+. See side effects and interactions
Tested athlete?WADA: Not WADA prohibited

What are NAD+ injections?

NAD+ is a coenzyme found in every cell that declines with age; it is not a peptide but is marketed alongside peptides as injections and infusions. Randomized trials show that oral precursors such as nicotinamide riboside and nicotinamide mononucleotide reliably raise blood NAD+ and that NMN modestly improved muscle insulin sensitivity in 25 prediabetic women, but hard clinical outcomes have not been demonstrated and intravenous NAD+ has only an 11 person pharmacokinetic pilot. NAD+ was nominated for the FDA 503A bulks list and has no final FDA determination, so compounded injections sit in a gray area, while oral precursors are sold as dietary supplements.

NAD+ is a coenzyme (a dinucleotide, not a peptide) central to redox metabolism and sirtuin and PARP signaling; sold as intravenous or subcutaneous NAD+ and as oral precursors. It is also known as Nicotinamide adenine dinucleotide, NAD, IV NAD+, NAD+ injection, Precursors: nicotinamide riboside (NR), nicotinamide mononucleotide (NMN), NAD injections, NAD+ IV therapy, NAD IV drip.

How does it work?

NAD+ shuttles electrons in glycolysis, the citric acid cycle, and oxidative phosphorylation, and is consumed as a substrate by sirtuins, PARP DNA repair enzymes, and CD38. Tissue NAD+ falls with age, partly because CD38 activity rises. Oral precursors (NR, NMN, niacin) enter the salvage pathway and raise cellular NAD+. Intravenous NAD+ is largely broken down in blood to nicotinamide and other metabolites before reaching cells, which is why the pharmacology of infusions differs from oral precursors.

Key facts
ClusterLongevity and mitochondrial
RoutesOral precursors: nicotinamide riboside, nicotinamide mononucleotide (dietary supplements); Intravenous infusion of NAD+ (clinics, compounded); Subcutaneous or intramuscular NAD+ injection (compounded); Intranasal and transdermal products exist without absorption data
Conditions studiedType 2 diabetes; Longevity and healthy aging; Insulin resistance and prediabetes; Muscle wasting and sarcopenia; Mitochondrial disease and dysfunction
Recordv3, reviewed, verified Sep 29, 2026

NAD+ IV therapy: what the evidence shows

Evidence: Human RCT evidenceGrade assigned per the methodology.

Human randomized trials exist mainly for precursors. Martens et al. 2018 (24 healthy middle aged and older adults, crossover, 6 weeks of NR 1,000 mg per day) found NR raised blood NAD+ by about 60% and was well tolerated, with a nonsignificant trend to lower blood pressure. Yoshino et al. 2021 (25 postmenopausal prediabetic women, 10 weeks of NMN 250 mg per day) found improved muscle insulin sensitivity by about 25% without changes in body composition or other metabolic markers. A 2025 meta-analysis found no meaningful effect of NR or NMN on muscle mass or function. For intravenous NAD+ itself, the only published human study is an 11 person pilot describing plasma and urine metabolites during a 6 hour infusion. A 2018 review summarizes the in vivo evidence for NAD boosting molecules, which is mostly rodent.

Indexed studies by evidence grade
Evidence typeIndexed studiesParticipants (human)
Human randomized trials349
Human observational studies111
Animal studies0n/a
All indexed studies460

Human evidence

Martens 2018: 24 adults aged 55 to 79, randomized crossover, NR 500 mg twice daily for 6 weeks raised blood NAD+ metabolome and was well tolerated; secondary blood pressure and arterial stiffness changes were not significant. Yoshino 2021: 25 overweight or obese postmenopausal women with prediabetes, NMN 250 mg per day for 10 weeks, muscle insulin stimulated glucose disposal improved about 25% versus no change on placebo, with no change in body weight, fat, or fasting glucose. Grant 2019: 11 healthy men received a 6 hour intravenous infusion of NAD+ at 3 umol per minute; plasma NAD+ did not rise until the second hour and metabolites accumulated in urine, with no clinical endpoints. Prokopidis 2025 meta-analysis: NR and NMN did not improve muscle mass or physical function across pooled trials.

Animal evidence

In mice, NR, NMN, and other NAD boosting strategies improve mitochondrial function, insulin sensitivity, and exercise capacity, and in some models extend life span or healthspan; sirtuin activation is the proposed pathway. Rajman, Chwalek, and Sinclair 2018 review the in vivo rodent evidence and note that human data lag well behind.

Key studies

Indexed studies of NAD+
StudyDesign and populationOutcomeGrade
Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults2018 PMID 29599478Randomized, double blind, placebo controlled crossover trial, 6 weeks per armn = 24 Healthy adults aged 55 to 79NR 1,000 mg per day raised blood NAD+ metabolome by about 60% and was well tolerated; nonsignificant trend toward lower blood pressureEvidence: Human RCT evidence
Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women2021 PMID 33888596Randomized, double blind, placebo controlled trial, 10 weeksn = 25 Overweight or obese postmenopausal women with prediabetesNMN 250 mg per day improved muscle insulin stimulated glucose disposal by about 25%; no change in body composition, fasting glucose, or other metabolic markersEvidence: Human RCT evidence
A pilot study investigating changes in the human plasma and urine NAD+ metabolome during a 6 hour intravenous infusion of NAD+2019 PMID 31572171Open label pharmacokinetic pilotn = 11 Healthy adult menPlasma NAD+ did not rise until the second hour of infusion; metabolites accumulated in urine; no clinical endpointsEvidence: Human observational evidence
The effect of nicotinamide mononucleotide and riboside on skeletal muscle mass and function: a systematic review and meta-analysis2025 PMID 40275690Systematic review and meta-analysis of randomized trialsAdults in randomized trials of NR or NMNNo significant effect of NR or NMN on muscle mass or physical functionEvidence: Human RCT evidence

Conditions studied

Conditions with evidence for NAD+
ConditionGradeNote
Type 2 diabetesNot gradedSeveral peptide drugs are FDA approved for type 2 diabetes, including insulin, GLP-1 receptor agonists, tirzepatide, and pramlintide. GLP-1 agonists and tirzepatide lower HbA1c by about 1 to 2 percentage points and reduce weight; semaglutide also reduces cardiovascular events.
Longevity and healthy agingEvidence: Human observational evidenceNot a peptide (a coenzyme). The record's human_rct grade is for muscle and metabolic endpoints of NAD+ precursors; there is no lifespan trial, and injectable NAD+ has no outcome trials.
Insulin resistance and prediabetesEvidence: Human RCT evidenceOral NMN 250 mg daily improved muscle insulin sensitivity by about 25% in 25 prediabetic women over 10 weeks; injectable NAD+ has not been tested for this.
Muscle wasting and sarcopeniaEvidence: Human RCT evidenceA meta-analysis found oral NR and NMN did not increase muscle mass or physical function.
Mitochondrial disease and dysfunctionEvidence: Human RCT evidenceOral NR 1,000 mg daily raised blood NAD+ by about 60% in older adults; no mitochondrial disease outcome trial.

Is NAD+ legal in the United States?

Regulatory: In FDA review (Category 1)WADA: Not WADA prohibited

FDA and compounding status

NAD+ (nicotinamide adenine dinucleotide) is not an FDA approved drug. As of the last verification date it is in FDA's 503A Category 1, the list of nominated bulk substances still under evaluation that FDA has not flagged as a significant safety risk. Under FDA's interim policy, FDA does not intend to act against a state-licensed 503A pharmacy that compounds with a Category 1 substance if the bulk ingredient comes from FDA-registered manufacturers with a valid certificate of analysis and the other 503A conditions are met. That protection lasts until FDA decides on listing by final rule or removes NAD+ from Category 1. One salt form, the beta disodium salt trihydrate, is in Category 3 and is not covered. State boards may add their own limits.

WADA status

Not WADA prohibited. Not named on the current prohibited list. Athletes should still confirm against the list in force for their season.

Regulatory timeline

No regulatory events recorded.

Full tracker for NAD+ or the category-wide tracker.

Email me when NAD+'s status changes

Email only. Alerts have not started yet; we will ask you to confirm before the first one. Unsubscribe any time.

What published studies of NAD+ used

Ranges below are reported from published studies and labeling only. PeptideAgent does not recommend doses or protocols.

Oral nicotinamide riboside 1,000 mg per day (500 mg twice daily) for 6 weeks (Martens 2018) and nicotinamide mononucleotide 250 mg per day for 10 weeks (Yoshino 2021) were the regimens used in randomized trials. The only intravenous NAD+ study infused 750 mg over 6 hours in 11 healthy men (Grant 2019). No clinical outcome based dose has been established for NAD+ infusions or injections.

Routes reported

Routes of administration reported for NAD+
#Route
1Oral precursors: nicotinamide riboside, nicotinamide mononucleotide (dietary supplements)
2Intravenous infusion of NAD+ (clinics, compounded)
3Subcutaneous or intramuscular NAD+ injection (compounded)
4Intranasal and transdermal products exist without absorption data

NAD+ side effects and interactions

Side effects

Side effects reported for NAD+
#Reported side effect
1Oral NR and NMN: generally well tolerated in trials; mild nausea, flushing, and fatigue reported
2IV NAD+: infusion related chest pressure, nausea, cramping, flushing, and anxiety when given quickly (reported clinically; drives slow infusion rates)
3Injection site reactions with subcutaneous NAD+
4Long term safety of chronically elevated NAD+ is unknown; theoretical concern about supporting tumor metabolism in animal models

Interactions

Interactions reported for NAD+
#Interaction
1No formal interaction studies for NAD+ infusions
2NAD precursors may add to the flushing of niacin containing products
3Theoretical interaction with PARP inhibitors used in oncology, since NAD+ is their substrate (not tested)

Contraindications

Contraindications for NAD+
#Contraindication
1Active cancer without oncologist input (theoretical, based on tumor metabolism in animal models)
2Pregnancy and breastfeeding (no data for injections or infusions)
3Rapid IV infusion in people with cardiac disease, given reported infusion reactions

How do people access NAD+ legally?

Typical cost: IV NAD+ at a published clinic menu costs about 450 to 900 USD per session for 500 to 1,000 mg (member prices from 400 USD); compounded subcutaneous NAD+ through telehealth is about 79 to 199 USD per month. Oral NR or NMN supplements are sold over the counter. Prices checked 2026-09-22 on published provider and pharmacy price pages.

Access options

  • Available

    Over the counter dietary supplement precursors (nicotinamide riboside, nicotinamide mononucleotide), no prescription needed.

  • Conditional

    Prescription from a licensed provider filled by a 503A compounding pharmacy for injectable NAD+, where the state board permits it.

  • Conditional

    Clinic or telehealth programs offering NAD+ infusions or injections.

Access paths are checked against public regulatory records. Products labeled research use only are never listed.

Compare NAD+

What's actually offered, and what that means for you

Licensed compounding pharmacies, clinics, and telehealth prescribers openly offer many unapproved peptides, and prescribers write prescriptions for them. [9] [10] [11]

NAD+ is not FDA approved. It is a nominated bulk substance FDA has not finished evaluating, and pharmacies compound it under FDA's interim policy where state boards permit, without any FDA finding on its safety or quality. [6] [12]

What FDA found

  • April 2026: FDA cited labeling defects on a 503B outsourcing facility's NAD+ and glutathione injections. [13]
  • January 2026: FDA told a 503B outsourcing facility that NAD+ is not on the 503B bulks list, and reported high endotoxin in an unopened vial of one of the facility's products. [14]
  • October 2024: FDA said compounders were making injectable NAD+ from food-grade NAD+, and that it had reports of severe chills, shaking, vomiting, and fatigue consistent with endotoxin. [15]

Enforcement is uneven. FDA mostly acts through warning letters to compounders and online sellers, Category 2 safety listings, and import alerts that let it detain shipments, rather than stopping every pharmacy. State pharmacy boards oversee pharmacies day to day, and their rules differ. [9] [16] [17] [18] [19] [20]

What that means for you

  • A pharmacy that compounds NAD+ relies on FDA's interim policy, which has conditions and which FDA can change, so it carries some regulatory risk. [12]
  • No FDA oversight of the specific product: FDA does not check a compounded drug's safety, effectiveness, or quality before it is sold. [20]
  • State boards can act. On August 19, 2026, Mississippi's medical, nursing, and pharmacy boards said no licensed provider may prescribe, recommend, supply, or administer a peptide that is not FDA approved, and that a consent form does not remove the provider's liability. [21]
  • Louisiana acted by statute: Act 374, in effect August 1, 2026, bars its licensing boards from prohibiting peptides only when they come from a pharmacy or outsourcing facility that complies with federal compounding law. It does not make any peptide eligible to compound. [22] [23]
  • Identity, purity, sterility, and dose accuracy can vary from batch to batch. [18]
  • Insurance rarely covers it, so you usually pay cash.

If you're going ahead anyway

These steps lower some risks. They do not make a compounded product safe, and FDA has not reviewed it. [20]

Check the pharmacy's license. Look the pharmacy up yourself on your state board of pharmacy's license search; FDA's BeSafeRx page links every state's. If the pharmacy is not listed, or is not licensed in your state, do not use it. [24] [25] [26]

What a legitimate prescription and consult look like. Federal law lets a pharmacy compound only for an identified patient on a valid prescription. A legitimate prescriber is licensed in the state where you are, evaluates you, and tells you the drug is compounded and not FDA approved, and a telehealth company should say which pharmacy compounds it. A seller that needs no prescription, or a pharmacy with no pharmacist to answer questions, is a warning sign. [11] [26] [27]

Why this is safer than a research-use-only product. A state-licensed pharmacy answers to its state board and has a pharmacist you can reach. A product labeled "research use only" or "not for human consumption" has neither, and FDA treats such products sold for people as unapproved drugs. In a 2024 study of semaglutide sold online without a prescription, half of six orders never arrived, and every vial that did was rated probably substandard or falsified, held more drug than its label said, and contained endotoxin. Black-market growth peptides have also contained modified molecules the label did not name. Safer is not safe: compounded drugs can also be contaminated or have too much or too little active ingredient. [20] [28] [29] [30] [31] [32]

Before you accept a compounded product, check for:

  • A 503A pharmacy licensed in your state (your state board of pharmacy publishes license lookups). [20]
  • A real evaluation by a licensed prescriber, not just an online form.
  • A certificate of analysis for the specific batch.

Questions to ask

  • Pharmacy: What is your license number, and are you licensed in my state? Then check it yourself on the state board's site. [24]
  • Telehealth company: Which pharmacy compounds and ships this, and is it a 503A pharmacy or a 503B outsourcing facility? [11]
  • Pharmacy: Is this made for me on a prescription written in my name? [27]
  • Prescriber: Are you licensed where I am, and will you evaluate me yourself rather than rely on a questionnaire? [11] [26]
  • Prescriber: What is the legal basis for a pharmacy to compound NAD+: is it on the 503A bulks list, or compounded under FDA's interim policy? [6] [12]
  • Anyone offering it: Does anyone call it "FDA approved", "generic", or from an "FDA-approved pharmacy"? None of these is true of a compounded drug, so the claim is a red flag. [11]

In Mississippi, there is no legitimate prescriber route for a peptide that is not FDA approved: licensed providers may not prescribe or supply one, and a patient who gets one on their own carries the risk alone. [21]

Frequently asked questions

What are NAD+ injections?

NAD+ injections are shots of nicotinamide adenine dinucleotide, a coenzyme found in every cell, usually given under the skin or into a muscle; NAD+ IV therapy infuses it into a vein over several hours. NAD+ is a coenzyme, not a peptide, though it is often sold alongside peptides. Both forms are compounded, not FDA approved: NAD+ has been nominated for the 503A bulks list without a final decision. No trial has tested NAD+ injections for a clinical outcome, and the only published IV study is an 11 person pilot. [3] [5] [6]

NAD+ IV therapy: what does the evidence show?

There is almost no evidence either way. The only published human study of intravenous NAD+ was an 11 person pilot that measured blood and urine metabolites during a 6 hour infusion and found much of the dose was broken down or excreted. No trial has compared IV NAD+ with oral precursors or measured clinical outcomes, so the several hundred dollar price is paid for an unproven benefit. [1] [3] [8]

What are the benefits of NAD+, and are they proven?

Not proven. Precursors reliably raise blood NAD+ in human trials, and one 25 person trial found NMN improved muscle insulin sensitivity by about 25% in prediabetic women. But no human trial has shown slower aging, longer life, or better physical function; a 2025 meta-analysis found no effect of NR or NMN on muscle mass or function. The longevity claims come from mouse studies. [2] [4] [5]

What are the side effects of NAD+?

Oral NR and NMN were well tolerated in randomized trials, with occasional mild nausea, flushing, or fatigue. IV NAD+ commonly causes chest pressure, nausea, cramping, and flushing when infused quickly, which is why clinics run it over hours. Long term safety of pushing NAD+ levels up is unknown, and animal work raises a theoretical concern about feeding tumor metabolism. [1] [3] [5]

Is NAD+ legal, and is it FDA approved?

NAD+ is not an FDA approved drug. Oral precursors such as nicotinamide riboside are lawful dietary supplements. Injectable and intravenous NAD+ are compounded from a bulk substance that has been nominated for the FDA 503A bulks list but has no final determination, so clinics offer it under FDA's interim enforcement discretion where state boards allow. Possessing or receiving it is not a crime. [6]

How is NAD+ taken in studies?

Trials used oral nicotinamide riboside 1,000 mg per day for 6 weeks and oral nicotinamide mononucleotide 250 mg per day for 10 weeks. The one IV study infused 750 mg over 6 hours. Clinic infusion and subcutaneous injection doses vary widely and have not been studied for outcomes. [1] [2] [3]

NAD+ vs NMN vs NR: which is better?

For raising blood NAD+, oral NR and NMN both work in randomized trials. NR has the larger safety database (Martens 2018 and others); NMN has the one trial showing a metabolic benefit (Yoshino 2021). Direct IV NAD+ has a single pharmacokinetic pilot and no outcome data. FDA has questioned NMN's status as a dietary ingredient, so its availability is less settled than NR's. [1] [2] [3]

Is NAD+ banned by WADA?

No. NAD+ and its precursors are naturally occurring vitamin B3 metabolites and are not listed in any section of the WADA Prohibited List as of 2026. Athletes should still verify supplement purity, since contamination is the main doping risk with supplements. [7]

Decisions about starting, stopping, or combining any treatment belong with a licensed clinician who knows your history.

From the blog

Sources

Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.

  1. [1]Martens CR et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun 2018PubMed 29599478, 2018
  2. [2]Yoshino M et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science 2021PubMed 33888596, 2021
  3. [3]Grant R et al. A pilot study investigating changes in the human plasma and urine NAD+ metabolome during a 6 hour intravenous infusion of NAD+. Front Aging Neurosci 2019PubMed 31572171, 2019
  4. [4]Prokopidis K et al. The effect of nicotinamide mononucleotide and riboside on skeletal muscle mass and function: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle 2025PubMed 40275690, 2025
  5. [5]Rajman L, Chwalek K, Sinclair DA. Therapeutic potential of NAD-boosting molecules: the in vivo evidence. Cell Metab 2018PubMed 29514064, 2018
  6. [6]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (links to the Category 1, 2, and 3 lists and the bulks list)FDA, 2026
  7. [7]WADA Prohibited ListWADA, 2026
  8. [8]Registered nurse staffed IV clinic published price menu (NAD+ and glutathione), accessed 2026-09-22
  9. [9]FDA: Compounding inspections, recalls, and other actions (warning letters to compounders)FDA
  10. [10]FDA warning letter 594743, April 1, 2020, to a state-licensed 503A compounding pharmacy (FDA warning letters database)FDA, 2020

Cite this page

Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.

APA style
PeptideAgent. (2026, September 29). NAD+: evidence, legality, and access. https://peptideagent.ai/peptides/nad-plus
HTML link
<a href="https://peptideagent.ai/peptides/nad-plus">NAD+: evidence, legality, and access</a>, PeptideAgent, updated September 29, 2026.